PARIS, France, Oct 13, 2021 – Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell progenitors Smart101 (ProTcell™) for rapid immune reconstitution, announced today that the institutional review board (IRB) of the Memorial Sloan Kettering Cancer Center (MSK) has approved the commencement of the Company’s phase 1/2 clinical trial. MSK will start enrolling patients in November, 2021.

PARIS, France, September 29th, 2021 – Smart Immune SAS’s unique ex-vivo biomimetic ProTcell™ ‘thymus in a dish’ platform technology, designed to generate specific human T-cell progenitor cells at scale with high purity, homogeneity, and yield, has been reinforced by data published in the peer-reviewed journal Cellular & Molecular Immunology

Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary Allogeneic T cell progenitor Product SMART 101 (ProTcell™) for AML and ALL

A l’hôpital Necker, une start-up mise sur un traitement post-greffe innovant

Smart Immune Announces the Launch of its T Cell Progenitor-based Platform of Next-Generation Biotherapies for Severe Infections and Leukemia .

Smart Immune will be in San Francisco

During the 38th annual J.P Morgan Healthcare conference. Following our latest announcement on the the launch of the T cell progenitor-based platform, we are looking forward to meeting there and share our latest progress.